Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
University Of South Florida Medical Center
mi
from
Tampa, FL
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
University Of South Florida Medical Center
mi
from
Tampa, FL
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Emory University
mi
from
Atlanta, GA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Medical College of Georgia
mi
from
Augusta, GA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Medical College of Georgia
mi
from
Augusta, GA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Columbus Research Institute
mi
from
Columbus, GA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Columbus Research Institute
mi
from
Columbus, GA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Northwestern University PD and Movement Disorders Center
mi
from
Chicago, IL
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Northwestern University PD and Movement Disorders Center
mi
from
Chicago, IL
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
University of Maryland Medical Center
mi
from
Baltimore, MD
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Boston University School of Medicine
mi
from
Boston, MA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Boston University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Parkinson's Disease and Movement Disorders Center of Albany
mi
from
Albany, NY
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Parkinson's Disease and Movement Disorders Center of Albany
mi
from
Albany, NY
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
North Shore Medical Center
mi
from
Manhasset, NY
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
North Shore Medical Center
mi
from
Manhasset, NY
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Columbia University Medical Center
mi
from
New York, NY
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
New York University
mi
from
New York, NY
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
New York University
mi
from
New York, NY
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
The Neurological Institute
mi
from
Charlotte, NC
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
The Neurological Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Duke University Health Systems
mi
from
Druham, NC
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Duke University Health Systems
mi
from
Druham, NC
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Cleveland Clinic
mi
from
Cleveland, OH
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Neurology Specialists
mi
from
Dayton, OH
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Neurology Specialists
mi
from
Dayton, OH
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Oregon Health and Science University
mi
from
Portland, OR
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Lankenau Medical Center
mi
from
Wynnewood, PA
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Lankenau Medical Center
mi
from
Wynnewood, PA
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Butler Hospital
mi
from
Providence, RI
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Baylor College of Medicine
mi
from
Houston, TX
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated:  10/28/2013
Hospital Español
mi
from
Buenos Aires,
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Status: Enrolling
Updated: 10/28/2013
Hospital Español
mi
from
Buenos Aires,
Click here to add this to my saved trials
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects
Status: Enrolling
Updated:  11/8/2013
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects
Status: Enrolling
Updated: 11/8/2013
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects
Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection)
Status: Enrolling
Updated:  11/12/2013
Duke University Health Center
mi
from
Durham, NC
Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects
Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection)
Status: Enrolling
Updated: 11/12/2013
Duke University Health Center
mi
from
Durham, NC
Click here to add this to my saved trials
Mild Cognitive Impairment in Parkinson's Disease
A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease
Status: Enrolling
Updated:  12/17/2013
University of Pennsylvania, Ralston House
mi
from
Philadelphia, PA
Mild Cognitive Impairment in Parkinson's Disease
A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease
Status: Enrolling
Updated: 12/17/2013
University of Pennsylvania, Ralston House
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of a Biomarker Related to the GI Tract for the Diagnosis of Parkinson's Disease
Lipopolysaccharide Binding Protein as a Potential Biomarker of Parkinson's Disease
Status: Enrolling
Updated:  1/23/2014
Rush University Medical Center
mi
from
Chicago, IL
Evaluation of a Biomarker Related to the GI Tract for the Diagnosis of Parkinson's Disease
Lipopolysaccharide Binding Protein as a Potential Biomarker of Parkinson's Disease
Status: Enrolling
Updated: 1/23/2014
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases
Status: Enrolling
Updated:  2/6/2014
San Francisco General Hospital
mi
from
San Francisco, CA
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases
Status: Enrolling
Updated: 2/6/2014
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
PET Study of Non-Motor Symptoms of Parkinson Disease
PET Study of Biochemistry and Metabolism of the CNS: Parkinson Disease
Status: Enrolling
Updated:  5/19/2014
University of Michigan Health System
mi
from
Ann Arbor, MI
PET Study of Non-Motor Symptoms of Parkinson Disease
PET Study of Biochemistry and Metabolism of the CNS: Parkinson Disease
Status: Enrolling
Updated: 5/19/2014
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
University of California at Los Angeles
mi
from
Los Angeles, CA
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
University of Florida
mi
from
Gainesville, FL
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
Cleveland Clinic
mi
from
Cleveland, OH
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated:  5/28/2014
Oregon Health and Science University
mi
from
Portland, OR
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial
Status: Enrolling
Updated: 5/28/2014
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
Status: Enrolling
Updated:  7/7/2014
University of South Florida
mi
from
Tampa, FL
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
Status: Enrolling
Updated: 7/7/2014
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Varenicline for Gait and Balance Impairment in Parkinson Disease
Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease
Status: Enrolling
Updated:  7/15/2014
Rush University Medical Center
mi
from
Chicago, IL
Varenicline for Gait and Balance Impairment in Parkinson Disease
Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease
Status: Enrolling
Updated: 7/15/2014
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Status: Enrolling
Updated:  7/17/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Status: Enrolling
Updated: 7/17/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
UCLA-University of California at Los Angeles(904)
mi
from
Los Angeles, CA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
UCLA-University of California at Los Angeles(904)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
San Francisco-University of California at San Francisco(905)
mi
from
San Francisco, CA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
San Francisco-University of California at San Francisco(905)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
VA Medical Center, San Francisco
mi
from
San Francisco, CA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
VA Medical Center, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
VA Greater Los Angeles Healthcare System, West LA
mi
from
West Los Angeles, CA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
VA Greater Los Angeles Healthcare System, West LA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
Portland-Oregon Health & science University(906)
mi
from
Portland, OR
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Portland-Oregon Health & science University(906)
mi
from
Portland, OR
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
VA Medical Center, Portland
mi
from
Portland, OR
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
VA Medical Center, Portland
mi
from
Portland, OR
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
Philadelphia-University of Pennsylvania Health System(901)
mi
from
Philadelphia, PA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Philadelphia-University of Pennsylvania Health System(901)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
VA Medical Center, Philadelphia
mi
from
Philadelphia, PA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
VA Medical Center, Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
Houston-Methodist Hospital(903)
mi
from
Houston, TX
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Houston-Methodist Hospital(903)
mi
from
Houston, TX
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
Michael E. DeBakey VA Medical Center (152)
mi
from
Houston, TX
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Michael E. DeBakey VA Medical Center (152)
mi
from
Houston, TX
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated:  11/25/2014
Richmond-Medical college of Virginia(902)
mi
from
Richmond, VA
Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation
CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort
Status: Enrolling
Updated: 11/25/2014
Richmond-Medical college of Virginia(902)
mi
from
Richmond, VA
Click here to add this to my saved trials
CNS Uptake of Intranasal Glutathione
Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease
Status: Enrolling
Updated:  1/14/2015
Univ of Washington
mi
from
Seattle, WA
CNS Uptake of Intranasal Glutathione
Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease
Status: Enrolling
Updated: 1/14/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease
ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease Phase I
Status: Enrolling
Updated:  2/4/2015
Rush University Medical Center
mi
from
Chicago, IL
ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease
ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease Phase I
Status: Enrolling
Updated: 2/4/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
Status: Enrolling
Updated:  5/26/2015
University of Nevada Las Vegas
mi
from
Las Vegas, NV
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease
Status: Enrolling
Updated: 5/26/2015
University of Nevada Las Vegas
mi
from
Las Vegas, NV
Click here to add this to my saved trials